Medibio Appoints Mental Healthcare Advocate and Former Congressman, Patrick Kennedy, to Board of Directors
(Thomson Reuters ONE) -
SYDNEY, Australia and MINNEAPOLIS, July 05, 2017 (GLOBE NEWSWIRE) -- Australian
Stock Exchange listed medical technology company Medibio Limited (MEB or the
Company) is pleased to announce the appointment of The Honourable Patrick J.
Kennedy to the Board of Directors.
Patrick J. Kennedy is a former member of the U.S. House of Representatives (D-
R.I.) and the nation's leading political voice on mental illness, addiction, and
other brain diseases. During his 16-year career representing Rhode Island in
Congress, he fought a national battle to end medical and societal discrimination
against these illnesses, highlighted by his lead sponsorship of the Mental
Health Parity and Addiction Equity Act of 2008. As a chief sponsor of one of
the major pieces of legislation of 2008, the Mental Health Parity Act, a bill
requiring most group health plans to provide coverage for the treatment of
mental illnesses that is comparable to what they provide for physical illnesses.
Mr. Kennedy was also recently appointed to President Trump's Commission on
Combating Drug Addiction and the Opioid Crisis. His political career and his
brave openness about his own health challenges provide unique expertise to
Medibio.
"Medibio's technology is truly groundbreaking, and has the potential to
fundamentally change the mental health system for the better. That's why I am
proud to be part of this team," said Kennedy. "This is a company that is truly
on the cutting edge, and their diagnostic and analytic tools will give
clinicians the power to treat patients more effectively, using better data, and
with a focus on better outcomes."
Medibio Managing Director and CEO, Jack Cosentino, said, "Patrick is a
significant addition to the Medibio Board! His wealth of experience gained from
serving in the U.S. Congress along with his advocacy for Mental Health will open
doors and heighten awareness for Medibio's technology. He has proved successful
in tackling Mental Health as one of the greatest challenges in healthcare
today. His knowledge, both through personal experience and legislative
accomplishments, will help guide us in laying the strategic foundations for
large-scale operations and the necessary payment and reimbursement coverage of
our innovative, new technology. We welcome Patrick to the board of Medibio and
value his leadership and passion to serve people with mental health conditions."
Following his 8th term serving in the U.S. Congress, Kennedy has become a
leading advocate for increased Mental Health & Addiction treatment coverage in
the United States. He is a co-founder of One Mind for Research, which seeks to
increase resources and collaboration in brain research and founder of the
Kennedy Forum which advances a roadmap to transform mental health and addiction
care.
Mr. Kennedy served three terms in the Rhode Island State legislature before he
was elected as a Democratic member of the United States House of Representatives
from 1995 to 2011. Kennedy served on the Armed Services Committee and the
Appropriations committee, where he served on the subcommittee on Veterans
Affairs and the Subcommittee on Labor, Health and Human Services, Education, and
the NIH. While in Congress, he was a vocal advocate for healthcare reform and
the chief sponsor of the 2008 Mental Health Parity and Addiction Equity Act.
Medibio Board Chair Chris Indermaur said, "Mr. Kennedy is a true win for
Medibio. His vast experience and credentials both with the government as well
as his current appointment serving on the White House commission will align well
with the challenges affecting those struggling with addiction and mental
illness. We are pleased to have him join our esteemed board."
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF), headquartered in Melbourne, Australia, with US
headquarters in Minneapolis, Minnesota, is an evidence-based medical technology
company that has developed an objective test to assist in the diagnosis and
management of depression, chronic stress and other mental health disorders.
Based on research conducted over 15 years at the University of Western
Australia, this test utilizes a panel of patented (and patent pending)
circadian, sleep and autonomic system biomarkers to objectively quantify and
characterize mental state. Medibio's depression diagnostic is being validated
in clinical studies undertaken by Johns Hopkins University School of Medicine
and The University of Ottawa, among others. The clinical trials will support
Medibio's application to become the first FDA approved, objective, and evidence
based approach to the diagnosis of mental health disorders. Medibio's technology
also provides an objective method for the assessment of stress and mental
wellbeing that can be translated to the workplace stress/wellbeing market,
wearable technology and App market. Medibio is listed on the Australian
Securities Exchange and trades on the OTCQB Venture Market for early stage and
developing U.S. and international companies. Investors can find Real-Time quotes
and market information for the company on www.otcmarkets.com and www.asx.com.au.
To learn more about Medibio visit www.Medibio.com.au.
+-----------------------------------------------------------------+
| Further Information: Website: www.medibio.com.au |
+--------------------------------+--------------------------------+
| Medibio Shareholder Enquiries: | |
| Jack Cosentino | Australian Media Enquiries: |
| CEO and Managing Director | Peter Taylor |
| Medibio Limited | NWR Communications |
| jack.cosentino(at)medibio.com.au | peter(at)nwrcommunications.com.au |
| T: +1 (952) 465 4787 | T: +61 (0) 412 036 231 |
+--------------------------------+--------------------------------+
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="US Gold Corp Increases Opportunity at its Keystone Asset with the Acquisition of Adjacent Gold Bar North Gold Exploration PropertyDatum: 05.07.2017 - 15:00 Uhr
Sprache: Deutsch
News-ID 551141
Anzahl Zeichen: 7070
contact information:
Town:
Savage
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 283 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medibio Appoints Mental Healthcare Advocate and Former Congressman, Patrick Kennedy, to Board of Directors"
steht unter der journalistisch-redaktionellen Verantwortung von
Medibio Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
